BioProcess International™ China

September 07 - 08, 2009 · The Westin Beijing Chaoyang Hotel · Beijing, China

Choose your language:

Event Overview

Explore China's bioprocessing needs and capabilities, and tap into the exploding potential of their biologics, biosimilars and vaccines market!

Featured Speakers

Berthold Bödeker, Ph.D.
Head Pilot Plants and Cell Culture
Bayer HealthCare AG

Marion F. Gruber, Ph.D.
Associate Director for Regulatory Policy, Center for Biologic Evaluation & Research, Office of Vaccine Research & Review
Food & Drug Administration

Geoffrey Allan, Ph.D.
President & CEO
Insmed Incorporated

Hear late-breaking reports and strategic insights in the plenary sessions focusing on:

Development and Production of Antibodies and Vaccines in China
Novel Biotherapeutics Case Studies
The Business and Regulatory Guidelines for Biosimilars/Follow-on Biologics
Process Development and Manufacturing Technology

Get up-to-date technical developments and experiences from international companies sharing their expertise on:

Cell Line Engineering & Development
Cell Culture
Analytical Characterization & Quality Control
Analytical Methods Development
Purification & Recovery
Protein Formulation
Manufacturing Infrastructure & Technology Transfer
Single Use / Disposables in Manufacturing

Simultaneous translation will be available for the entire conference

Why BioProcessing in China?

Despite the global economic downturn, economists are still projecting in China? a positive growth rate for China in 2009. Much of this growth will come from China's biotech sector. China government's initiatives, the SFDA's tightening of guidelines, the increasing IP, GMP and GLP compliance, the continuing search for lower cost production and the abundance of talent in China are all contributing to the sustained growth in the China's biopharmaceutical sector. While China's drug manufacturers have traditionally focused on generics, traditional Chinese medicine or API manufacturing, there's a growing trend towards new drug R&D among the more progressive drug companies as well as new biotechs. Proprietary proteins and antibodies, biosimilars, and private vaccines are beginning to make their way into the portfolios of many drug companies in China. In addition, Western pharmaceuticals are increasingly looking toward China for untapped potential.

This is the stage against which IBC's BioProcess International™ China is set.

BioProcess Internatioanl™ China aims to address the skill-sets and capabilities required by China's biotech and pharmaceutical companies to move to the forefront of biopharm processing and manufacturing, and be a major player in the industry. The event will present topics covering the components of the bioprocess value-chain, ranging from Cell Culture to Formulation; from Microbial Fermentation to Purification and Recovery; from Analytical Methods to Single Use/Disposables etc. Industry trends and developments of novel proteins and antibodies, me-too and me-better drugs as well as therapeutic vaccine advances will be presented in plenary sessions. Hotly debatable topics such as IP, Investment and Regulatory will also be addressed in roundtables and panel discussions.

If you're working in the Bioprocessing field, you cannot afford to miss this event! Join us now and get ready to uncover China's untapped potential!